Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2026 11:40 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote—EXAS, SNDA, FSUN, and TBN

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
February 05, 2026 10:38 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—UBFO, SNDA, FSUN, and TBN

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
November 05, 2025 17:30 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonida Senior Living, Inc. (NYSE: SNDA)

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
October 01, 2025 01:00 ET | Source: Pharming Group N.V.

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Pharming sNDA for leniolisib in children aged 4-11 years with APDS accepted and granted Priority Review by FDA.
February 11, 2025 07:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
December 16, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis today announced the submission of an sNDA to the FDA for ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 for mild to moderate AD.
December 12, 2024 06:59 ET | Source: Sobi, Inc.

Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...
September 24, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
July 23, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the submission of an sNDA in scalp and body psoriasis.
March 15, 2024 15:34 ET | Source: Optinose, Inc.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical...